Posted by Michael Wonder on 28 May 2020
COVID-19: researchers halt patient recruitment for hydroxychloroquine trial
28 May 2020 - Australian researchers have suspended patient recruitment in a major clinical trial of the controversial anti-malaria drug hydroxychloroquine.
The Doherty Institute announced the pause on the ASCOT trial, which was to involve 2000 patients with COVID-19 in Australia and internationally, following the publication of a study in the Lancet which cast doubt on the treatment.
The Lancet study found people taking hydroxychloroquine were at higher risk of death and heart problems, and that there was no benefit to treating coronavirus patients with the drug.
